[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604823":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":26,"responsibleParty":42,"collaborators":45,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"University of Ulm","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Immunoadsorption",null,"Patients receiving Immunoadsorption as an escalation therapy after unsuccessful treatment with immunoglobulins or steroids",[13],{"name":14,"affiliation":5,"role":15},"Johannes Dorst","PRINCIPAL_INVESTIGATOR",[17,22],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Johannes Dorst, Prof. Dr.","CONTACT","+497311775285","johannes.dorst@uni-ulm.de",{"name":23,"role":19,"phone":24,"phoneExt":10,"email":25},"Zeynep Elmas","+497311775282","zeynep.elmas@uni-ulm.de",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Ulm","Baden-Wurttemberg","89081","Germany","DE",{"type":35,"coordinates":36},"Point",[37,38],9.99155,48.39841,{"lat":38,"lon":37},[41],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},{"type":15,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Albert Christian Ludolph, Prof.","Prof. Dr.",[46],{"name":47,"class":48},"Fresenius Medical Care Deutschland GmbH","INDUSTRY","100604823","immunoadsorption-for-treatment-of-chronic-inflammatory-demyelinating-polyneuropathy-cidp-100604823",false,"NCT07154524","Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","IFTOC","Inclusion Criteria:\n\n* Diagnosis of CIDP based on the EAN\u002FPNS Guidelines on Diagnosis and Treatment of CIDP13\n* age ≥ 18 years\n* Willing and capable of giving written informed consent\n* Currently receiving IVIg or MP treatment OR starting IVIg or MP treatment at baseline\n\nExclusion Criteria:\n\n* none","ALL","18 Years",{"count":59,"type":60},140,"ESTIMATED","OBSERVATIONAL","This study is designed as an explorative study aiming at exploring safety and efficacy of immunoadsorption (IA) in patients with Chronic Inflammatory Demyelinating Poly-neuropathy (CIDP) compared to intravenous immunoglobulins (IVIg) and methyl-prednisolone (MP). For this purpose, approximately 140 patients with CIDP will be included within the framework of the German multicenter network \"Kompetenznetz Peripherer Nerv\" (KKPNS).\n\nThe study will be purely observational. IA will be performed as an escalation therapy, i.e., in patients who did not respond to IVIg and\u002For MP treatment. Patients will be included in the study during ongoing IVIg or MP treatment and switched to IA during the 18-month observation period in case of an insufficient response. IA will be performed according to the therapeutic scheme of each participating center. A non-mandatory recommendation for number of sessions, treatment volumes, and frequency will be given (see below). Six-month follow-up visits including collection of standardized clini-cal data will be performed.",[64],"Chronic Inflammatory Demyelinating Polyneuropathy",[64,9,66,67],"Long-term effects","therapy-refractory","2025-09-04",{"date":70,"type":71},"2025-09-11","ACTUAL",{"date":73,"type":71},"2025-08-27",{"date":75,"type":60},"2029-08-27",{"name":5,"class":6},1]